ClearSky heads to Hong Kong for MDS 2018

ClearSky heads to Hong Kong for MDS 2018

ClearSky Medical Diagnostics will be heading to Hong Kong in October for the 22nd International Congress of Parkinson’s Disease and Movement Disorders (MDS). The Congress will bring together world-renowned delegates sharing information on neurodegenerative and...
ClearSky celebrates Humies success at GECCO 2018

ClearSky celebrates Humies success at GECCO 2018

ClearSky Medical Diagnostics is proud to be part of an award-winning team that scooped top prize in the Human-Competitive Awards (Humies) 2018 in Japan. The Humies Awards recognise work that has not just solved some problem via techniques from evolutionary computation...
What is levodopa-induced dyskinesia?

What is levodopa-induced dyskinesia?

Levodopa is the most effective and commonly used drug for treating Parkinson’s. It is a chemical building-block that your body converts into dopamine. People with Parkinson’s lack enough dopamine because some of the brain cells that make it have died. The loss of...
What are evolutionary algorithms?

What are evolutionary algorithms?

ClearSky Medical Diagnostics’ portfolio of non-invasive devices for diagnosing and monitoring neurodegenerative conditions is based on unique biologically-inspired technology. We use a range of standard peripherals, including tablets, sensors, and data gloves, to...
Dr Morris strengthens the ClearSky team

Dr Morris strengthens the ClearSky team

Dr Keith Morris has been appointed the Quality Assurance and Regulatory Affairs Counsel for ClearSky Medical Diagnostics. Keith has more than 20 years’ experience in the pharmaceutical, healthcare and medical industries and huge experience of regulatory and quality...